Soligenix Inc. (NASDAQ:SNGX) insider Spa Essetifin bought 293,510 shares of the stock in a transaction that occurred on Wednesday, November 29th. The stock was bought at an average price of $2.12 per share, with a total value of $622,241.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Soligenix Inc. (NASDAQ:SNGX) traded up $0.05 during trading on Friday, reaching $2.08. 31,200 shares of the company were exchanged, compared to its average volume of 259,422. Soligenix Inc. has a 52-week low of $1.74 and a 52-week high of $5.08.

Soligenix (NASDAQ:SNGX) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.15. Soligenix had a negative net margin of 90.93% and a negative return on equity of 112.81%. The company had revenue of $1.82 million during the quarter, compared to the consensus estimate of $1.36 million. equities analysts anticipate that Soligenix Inc. will post -1.28 EPS for the current year.

SNGX has been the subject of a number of recent analyst reports. Maxim Group set a $5.00 target price on shares of Soligenix and gave the company a “buy” rating in a report on Tuesday, October 24th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Soligenix in a report on Thursday, September 21st.

TRADEMARK VIOLATION NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/01/soligenix-inc-sngx-insider-spa-essetifin-buys-293510-shares.html.

About Soligenix

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Receive News & Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.